|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hou X, Zhang M and Qiao H: Diagnostic
significance of miR-106a in gastric cancer. Int J Clin Exp Pathol.
8:13096–13101. 2015.PubMed/NCBI
|
|
3
|
Zeng X, Xiang J, Wu M, Xiong W, Tang H,
Deng M, Li X, Liao Q, Su B, Luo Z, et al: Circulating miR-17,
miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers
in nasopharyngeal carcinoma. PLoS One. 7:e463672012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schwarzenbach H, Nishida N, Calin GA and
Pantel K: Clinical relevance of circulating cell-free microRNAs in
cancer. Nat Rev Clin Oncol. 11:145–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bianchi F: Lung cancer early detection:
the role of circulating microRNAs. EBioMedicine. 2:1278–1279. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mirzaei HR, Sahebkar A, Mohammadi M, Yari
R, Salehi H, Jafari MH, Namdar A, Khabazian E, Jaafari MR and
Mirzaei H: Circulating microRNAs in hepatocellular carcinoma:
potential diagnostic and prognostic biomarkers. Curr Pharm Des.
22:5257–5269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vickers KC and Remaley AT: Lipid-based
carriers of microRNAs and intercellular communication. Curr Opin
Lipidol. 23:91–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ganepola GA, Rutledge JR, Suman P,
Yiengpruksawan A and Chang DH: Novel blood-based microRNA biomarker
panel for early diagnosis of pancreatic cancer. World J
Gastrointest Oncol. 6:22–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsujiura M, Ichikawa D, Komatsu S,
Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi
K, Fujiwara H, et al: Circulating microRNAs in plasma of patients
with gastric cancers. Br J Cancer. 102:1174–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Imaoka H, Toiyama Y, Okigami M, Yasuda H,
Saigusa S, Ohi M, Tanaka K, Inoue Y, Mohri Y and Kusunoki M:
Circulating microRNA-203 predicts metastases, early recurrence, and
poor prognosis in human gastric cancer. Gastric Cancer. 19:744–753.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng G: Circulating miRNAs: Roles in
cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev.
81:75–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fonsato V, Collino F, Herrera MB,
Cavallari C, Deregibus MC, Cisterna B, Bruno S, Romagnoli R,
Salizzoni M, Tetta C, et al: Human liver stem cell-derived
microvesicles inhibit hepatoma growth in SCID mice by delivering
antitumor microRNAs. Stem Cells. 30:1985–1998. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiang M, Zeng Y, Yang R, Xu H, Chen Z,
Zhong J, Xie H, Xu Y and Zeng X: U6 is not a suitable endogenous
control for the quantification of circulating microRNAs. Biochem
Biophys Res Commun. 454:210–214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer-Verlag; New York, NY: 2009
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−ΔΔC(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang Z, Yin J, Fu W, Mo Y, Pan Y, Dai L,
Huang H, Li S and Zhao J: miRNA 17 family regulates
cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC.
PLoS One. 9:e946392014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Babu KR and Muckenthaler MU: miR-20a
regulates expression of the iron exporter ferroportin in lung
cancer. J Mol Med (Berl). 94:347–359. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Safari A, Seifoleslami M, Yahaghi E,
Sedaghati F and Khameneie MK: RETRACTED ARTICLE: Upregulation of
miR-20a and miR-10a expression levels act as potential biomarkers
of aggressive progression and poor prognosis in cervical cancer.
Tumour Biol. Oct 1–2015.(Epub ahead of print).
|
|
19
|
Zhang Y, Zheng L, Ding Y, Li Q, Wang R,
Liu T, Sun Q, Yang H, Peng S, Wang W, et al: miR-20a induces cell
radioresistance by activating the PTEN/PI3K/Akt signaling pathway
in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys.
92:1132–1140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sokolova V, Fiorino A, Zoni E, Crippa E,
Reid JF, Gariboldi M and Pierotti MA: The effects of miR-20a on
p21: two mechanisms blocking growth arrest in TGF-β-responsive
colon carcinoma. J Cell Physiol. 230:3105–3114. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Azizian A, Kramer F, Jo P, Wolff HA,
Beißbarth T, Skarupke R, Bernhardt M, Grade M, Ghadimi BM and
Gaedcke J: Preoperative prediction of lymph node status by
circulating mir-18b and mir-20a during chemoradiotherapy in
patients with rectal cancer. World J Surg. 39:2329–2335. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qiang XF, Zhang ZW, Liu Q, Sun N, Pan LL,
Shen J, Li T, Yun C, Li H and Shi LH: miR-20a promotes prostate
cancer invasion and migration through targeting ABL2. J Cell
Biochem. 115:1269–1276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu R, Zhang C, Hu Z, Li G, Wang C, Yang
C, Huang D, Chen X, Zhang H, Zhuang R, et al: A five-microRNA
signature identified from genome-wide serum microRNA expression
profiling serves as a fingerprint for gastric cancer diagnosis. Eur
J Cancer. 47:784–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du Y, Zhu M, Zhou X, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W, et al: miR-20a enhances cisplatin
resistance of human gastric cancer cell line by targeting NFKBIB.
Tumour Biol. 37:1261–1269. 2016. View Article : Google Scholar : PubMed/NCBI
|
